{"id":"NCT02720744","sponsor":"Avadel","briefTitle":"Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy","officialTitle":"A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-17","primaryCompletion":"2020-03-25","completion":"2020-03-25","firstPosted":"2016-03-28","resultsPosted":"2022-03-22","lastUpdate":"2022-03-22"},"enrollment":212,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Excessive Daytime Sleepiness","Cataplexy","Narcolepsy"],"interventions":[{"type":"DRUG","name":"FT218","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sodium Oxybate","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether once-nightly FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.","primaryOutcome":{"measure":"Maintenance of Wakefulness Test (MWT)","timeFrame":"Study Visit 8 at 14 weeks","effectByArm":[{"arm":"FT218","deltaMin":10.8,"sd":0.96},{"arm":"Placebo","deltaMin":4.7,"sd":0.92}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":57,"countries":["United States","Australia","Canada","Czechia","France","Germany"]},"refs":{"pmids":["40851446","40111739","40111738","39321628","39153911","35380374","34358324"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":77},"commonTop":["Enuresis","Headache","Dizziness","Vomiting","Nausea"]}}